Endocrine orbitopathy – the topic still alive

Czech version

Authors: Zdeněk Fryšák; David Karásek; Milan Halenka
Authors‘ workplace: III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
Published in: Vnitř Lék 2016; 62(Suppl 3): 56-62
Category: Reviews

Overview

Endocrine orbitopathy (EO) must be understood mainly as a result of oxidative stress. The pathological process finally affects both the appearance and vision of the patient. In the case of inappropriate or late treatment or lack of patient cooperation, it significantly influences the quality of life of those affected. In spite of the sophisticated diagnostic algorithms, in some cases it is difficult to confirm the diagnosis of EO. The range of laboratory methods, the essential part of the diagnostic process, has only recently been extended by the possibility of quantification of specific, stimulating immunoglobulins (TSI). A major shortcoming may be seen in an undervalued importance of orbital ultrasonography, in particular of the eye muscles (US).

Key words:
biological treatment – endocrine orbitopathy (EO) – Graves-Basedow disease (GB) – “hashitoxicosis” (HTX) – hyaluronan synthase 2 (HAS2) – thyroid-blocking immunoglobulins (TBI) – thyroid-stimulating immunoglobulins (TSI) – hyaluronic acid (HA) – lymphocytary, Hashimoto‘s thyroiditis (HT) – pulse therapy – TSH-receptor – transcription factors FOXOs – orbital ultrasonography, mainly of the eye muscles (US)

Sources

1. Campi I, Vannucchi G, Salvi M. Therapy of endocrine disease: Endocrine Dilemma: Management of Graves‘ Orbitopathy. Eur J Endocrinol 2016; 175(3): R117–33. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-15–1164>.

2. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves‘ ophthalmopathy. Thyroid 2002; 12(10): 855–860.

3. Werner SC. Classification of the eye changes of Grave‘s disease. J Clin Endocrinol Metab 1969; 29(7): 982–984. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem-29–7-982>.

4. Karhanová M, Kalitová J Endokrinní orbitopatie z pohledu oftalmologa. Med Praxi 2013; 10(2): 68–71.

5. Chaudhry IA. IgG4-Related Orbitopathy. Middle East Afr J Ophthalmol 2015; 22(4): 405–406. Dostupné z DOI: <http://dx.doi.org/10.4103/0974–9233.167816>.

6. Hrdá P, Novák Z, Šterzl I. Endokrinní orbitopatie. Maxdorf: Praha 2009. ISBN 978–80–7345–194–3.

7. Werner SC. Modification of the classification of the eye changes of Graves‘ disease. Am J Ophthalmol 1977; 83(5): 725–727.

8. Mourits MP, Prummel MF, Wiersinga WM et al. Clinical activity score as a guide in the management of patients with Graves‘ ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47(1): 9–14. Erratum in: Clin Endocrinol (Oxf) 1997; 47(5): 632.

9. Wiersinga WM, Perros P, Kahaly GJ et al. Clinical assessment of patients with Graves‘ orbitopathy: the European Group on Graves‘ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006; 155(3): 387–389. Dostupné z DOI: <http://dx.doi.org/10.1530/eje.1.02230>.

10. Bartalena L, Baldeschi L, Dickinson AJ et al. Consensus statement of the European group on Graves‘ orbitopathy (EUGOGO) on management of Graves‘ orbitopathy. Thyroid 2008; 18(3): 333–346. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2007.0315>.

11. Dolman PJ, Rootman J. VISA Classification for Graves orbitopathy. Ophthal Plast Reconstr Surg 2006; 22(5): 319–324. Dostupné z DOI: <http://dx.doi.org/10.1097/01.iop.0000235499.34867.85>.

12. Dolman PJ. Evaluating Graves‘ orbitopathy. Best Pract Res Clin Endocrinol Metab 2012; 26(3): 229–248. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beem.2011.11.007>.

13. Yang M, Wiersinga WM, Soeters MR et al. What is the aim of immunosuppressive treatment in patients with graves‘ orbitopathy? Ophthal Plast Reconstr Surg 2014; 30(2): 157–161. Dostupné z DOI: <http://dx.doi.org/10.1097/IOP.0000000000000036>.

14. Perros P, Žarković M, Azzolini C et al. PREGO (presentation of Graves‘ orbitopathy) study: changes in referral patterns to European Group On Graves‘ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 2015; 99(11): 1531–1535. Dostupné z DOI: <http://dx.doi.org/10.1136/bjophthalmol-2015–306733>.

15. Karhanová M, Kovář R, Fryšák Z et al. Extraocular muscle involvement in patients with thyroid-associated orbitopathy. Česk Slov Oftalmol 2014; 70(2): 66–71.

16. Karhanova M, Kovar R, Frysak Z et al. Correlation between magnetic resonance imaging and ultrasound measurements of eye muscle thickness in thyroid-associated orbitopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(2): 307–312. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2014.001>.

17. Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol 2011; 95(12): 1670–1674. Dostupné z DOI: <http://dx.doi.org/10.1136/bjophthalmol-2011–300487>.

18. Forbes G, Gorman CA, Brennan MD et al. Ophthalmopathy of Graves‘ disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol 1986; 7(4): 651–656.

19. Anderson RL, Tweeten JP, Patrinely JR et al. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg 1989; 20(8): 568–574.

20. Endo T, Ohno M, Kotani S et al. Thyrotropin receptor in non-thyroid tissues. Biochem Biophys Res Commun 1993; 190(3): 774–779. Dostupné z DOI: <http://dx.doi.org/10.1006/bbrc.1993.1116>.

21. Paschke R, Metcalfe A, Alcalde L et al. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab 1994; 79(5): 1234–1238.

22. Bahn RS, Dutton CM, Natt N et al. Thyrotropin receptor expression in Graves‘ orbital adipose/connective tissues: potential autoantigen in Graves‘ ophthalmopathy. J Clin Endocrinol Metab 1998; 83(3): 998–1002.

23. Urbánek P, Klotz LO. Posttranscriptional regulation of FOXO expression: microRNAs and beyond. Br J Pharmacol 2016. Dostupné z DOI: <http://dx.doi.org/10.1111/bph.13471>.

24. Zhang L, Ji QH, Ruge F et al. Reversal of Pathological Features of Graves‘ Orbitopathy by Activation of Forkhead Transcription Factors, FOXOs. J Clin Endocrinol Metab 2016; 101(1): 114–122. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015–2932>.

25. Evans M, Sanders J, Tagami T et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf) 2010; 73(3): 404–412. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2010.03831.x>.

26. Kampmann E, Diana T, Kanitz M et al. Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study. Int J Endocrinol 2015; 2015: 678194. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/678194>.

27. Eckstein AK, Plicht M, Lax H et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves‘ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91(9): 3464–3470.

28. Bjørgaas MR, Farstad H, Christiansen SC et al. Impact of thyrotropin receptor antibody levels on fetal development in two successive pregnancies in a woman with Graves‘ disease. Horm Res Paediatr 2013; 79(1): 39–43. Dostupné z DOI: <http://dx.doi.org/10.1159/000342644>.

29. Sawicka-Gutaj N, Gutaj P, Sowiński J et al. Influence of cigarette smoking on thyroid gland-an update. Endokrynol Pol 2014; 65(1): 54–62. Dostupné z DOI: <http://dx.doi.org/10.5603/EP.2014.0008>.

30. Xing L, Ye L, Zhu W et al. Smoking was associated with poor response to intravenous steroids therapy in Graves‘ ophthalmopathy. Br J Ophthalmol 2015; 99(12): 1686–1691. Dostupné z DOI: <http://dx.doi.org/10.1136/bjophthalmol-2014–306463>.

31. Nĕmec J, Vána S, Zamrazil V. Endocrine ophthalmopathy from the viewpoint of the endocrinologist. Cesk Oftalmol 1983; 39(2): 108–110.

32. Stein JD, Childers D, Gupta S et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 2015; 133(3): 290–296. Dostupné z DOI: <http://dx.doi.org/10.1001/jamaophthalmol.2014.5103>.

33. Salvi M, Vannucchi G, Campi I et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006; 154(4): 511–517.

34. Chang TC, Liao SL. Slow-release lanreotide in Graves‘ ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006; 29(5): 413–422.

35. Chen H, Mester T, Raychaudhuri N et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 2014; 99(9): E1635-E1640. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–1580>.

36. Salvi M, Vannucchi G, Currò N et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves‘ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015; 100(2): 422–431. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–3014>.

37. Westhovens R, Kremer JM, Emery P et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 2014; 32(4): 553–562.

38. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352(25): 2598–2608.

39. Kalunian KC, Davis JC Jr., Merrill JT et al. IDEC-131 Lupus Study Group.Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(12): 3251–3258.

40. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004; 25(6): 899–918.

41. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28(12): 551–558.

42. Marcocci C, Bartalena L. Role of oxidative stress and selenium in Graves‘ hyperthyroidism and orbitopathy. J Endocrinol Invest 2013; 36(10 Suppl): 15–20.

43. Dharmasena A. Selenium supplementation in thyroid associated ophthalmopathy: an update. Int J Ophthalmol 2014; 7(2): 365–375. Dostupné z DOI: <http://dx.doi.org/10.3980/j.issn.2222–3959.2014.02.31>.

44. Türke B, Balázs C. Treatment of pretibial myxoedema with pentoxifylline. Orv Hetil 2012; 153(43): 1719–1722. Dostupné z DOI: <http://dx.doi.org/10.1556/OH.2012.29472>.

45. Noh JY, Hamada N, Inoue Y et al. Thyroid-stimulating antibody is related to Graves‘ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves‘ disease. Thyroid 2000; 10(9): 809–813.

46. Li Y, Kim J, Diana T et al. A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity. Clin Exp Immunol 2013; 173(3): 390–397. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12129>.

47. Many MC, Costagliola S, Detrait M et al. Development of an animal model of autoimmune thyroid eye disease. J Immunol 1999; 162(8): 4966–4974.

48. Tabasum A, Khan I, Taylor P et al. Thyroid antibody-negative euthyroid Graves‘ ophthalmopathy. Endocrinol Diabetes Metab Case Rep 2016; 2016: 160008. Dostupné z DOI: <http://dx.doi.org/10.1530/EDM-16–0008>.